News

AOD-9604 vs. Semaglutide Bone Risk: What the New GLP-1 Bone Study Means
New rodent data links semaglutide to reduced bone formation, raising questions about fracture risk. Could fragment peptides like AOD-9604 offer fat loss Read more...
Semaglutide Bone Health: Fracture Risk vs. Menopause Loss
Semaglutide has become a central tool in weight-loss medicine. The compound drives significant fat loss through GLP-1 receptor activation. Yet a paradox emer... Read more...
ACP First-Line Recommendation: What Semaglutide's New Clinical Guidelines Mean for Your Weight Loss Protocol
The ACP now lists semaglutide as first-line pharmacotherapy for obesity. What does this mean for weight-loss protocols, and where do other metabolic peptides fit? Read more...
Does Sex or Comorbidity Predict Semaglutide Weight Loss?
Semaglutide produces substantial weight loss in clinical trials. Average reductions of 15 to 20 percent of body weight appear across multiple studies. But av... Read more...